Our approach is to target the first stress signal coming from the epithelium in the context of mucosal inflammatory disorders (MIDs). Doing so, we reinstate epithelial homeostasis by preventing inflammation, fibrosis and disruption of epithelial integrity. We also bring safety to patients as our approach is not immunosuppressive.
Our approach is to target the first stress signal coming from the epithelium in the context of mucosal inflammatory disorders (MIDs). Doing so, we reinstate epithelial homeostasis by preventing inflammation, fibrosis and disruption of epithelial integrity. We also bring safety to patients as our approach is not immunosuppressive.
The company is managed by a highly-experienced and complementary team, supported by a scientific team consisted by 3 scientific founders who are used to entrepreunarial experiences, and who conducted academic research (at INSERM and AP-HP) over the past decade to identify the new target.
The company is managed by a highly-experienced and complementary team, supported by a scientific team consisted by 3 scientific founders who are used to entrepreunarial experiences, and who conducted academic research (at INSERM and AP-HP) over the past decade to identify the new target.